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A glutamic acid to lysine change in the Z variant of human a,-antitrypsin is associated with a failure to secrete the protein from synthesising cells. 
The block in export of the protein may be caused either by the loss of an acidic residue or the introduction of a basic one at this point in the 
polypeptide chain. Site-directed mutagenesis has been used to construct novel %-antitrypsin mutants which show that the side chain interactions 
from Glu-342 are not obligatory for protein export and it is rather the introduction of a basic residue at this point which produces the intracellular 
accumulation of the protein. 
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1. INTRODUCTION 
A variety of plasma proteins contribute towards the 
protease inhibitory capacity of the blood, foremost 
among them is the glycoprotein ari-antitrypsin [l-33. 
The protein is more systematically known as al-anti- 
protease since its normal physiological target is not 
trypsin but neutrophil elastase, thus the protein’s main 
function is to protect elastic fibres in the alveoli from 
hydrolysis by this protease. The protein is encoded by 
a gene 12.2 kb in length found on human chromosome 
14 [4] at a genetic locus designated Pi. The highly 
polymorphic nature of this locus gives rise to a large 
number of ai-antitrypsin variants in the human popu- 
lation. The most common allele is referred to as PiM 
and this variant type can be further divided into six 
distinct sub-classes. Individuals homozygous for PiM 
alleles have plasma cYi-antitrypsin levels in the range 
150-350 mg/dl and exhibit no apparent clinical symp- 
toms IS]. Homozygosity for the abnormal Z variant, 
however, is associated with serum levels of the inhibitor 
< 50 mg/dl and the development of emphysema due to 
the loss of lung elasticity and, in a proportion of cases, 
infantile liver disease 161. The Z protein is synthesised 
in normal amounts but poorly secreted from the 
hepatocytes o the deficit of inhibitor in the circulation 
is allied to an accumulation in the endoplasmic 
reticulum of synthesising cells [6,7]. 
for Val-213 to Ala-213 while a G-to-A change in exon 
V produces Glu-342 to Lys-342 [8,9]. The first of these 
changes is conservative and also appears in 23% of M 
haplotypes so it is thought to have no effect on the 
secretion of the protein. The second mutation has a 
radical effect on the charge of the molecule and pro- 
foundly influences its secretion from liver cells [lo], 
and Xenopus oocytes injected with encoding mRNA 
Ill, 121. Crystallographic measurements on a cleaved 
form of the normal inhibitor have suggested that 
Glu-342 forms a salt bridge with Lys-290 113). The loss 
of this structural feature in the Pi2 variant, caused by 
the Glu-342 to Lys-342 substitution, has been put for- 
ward as the reason for defective secretion of the mutant 
protein and its intracellular accumulation [ 13,141. 
Oligonucleotide mutagenesis has been used to 
demonstrate that disruption of this salt bridge by 
substitution of the residue at 290 has little effect on 
secretion of the mutant proteins [ 15-171. Here we 
demonstrate that it is the nature of residue 342 itself, 
rather than its participation in a salt bridge per se which 
profoundly effects the secretion of hi-antitr~sin. 
2. MATERIALS AND METHODS 
Two changes in primary sequence distinguish the M 
and 2 proteins. A T-to-C transition in exon III codes 
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Mutant cDNAs were cloned into the modified vector SP64T for in 
vitro transcription using SP6 polymerase 1151. The preparation and 
micro-injection of Xenopus oocytes was as described by Colman [20]. 
Oocyte extracts and incubation media were immunoprecipitated us- 
ing anti-human cur-antitrypsin (DAK0 Immunoglobulins a/s) an$the 
products analysed on 12.5% SDS-polyacrylamide gels followed by 
fluorography using ‘Amplify’ (Amersham International plc) [15]. 
Constructs of the mutagenised cDNAs ligated into the eukaryotic 
expression vector pSV2 were transfected into NIH 3T3 cells by 
calcium phosphate co-precipitation 1211. Transfection efficiency was 
determined by counting the number of G418-resistant colonies 10 
days after G418 selection compared to no selected cells. Stable 
transfected cells and an equivalent aliquot of culture medium were 
analysed by gel electrophoresis and Western blotting [ 191 and indirect 
ELISA [22]. 
3. RESULTS AND DISCUSSION 
Oligonucleotide directed mutagenesis was used to 
construct a series of cur-antitrypsin mutants that en- 
coded single amino acid substitutions at position 342. 
These mutants were designed to introduce alternatively 
charged side chains at this position and disrupt the 
putative salt bridge between the glutamic acid residue 
found at this position in the normal, PiM inhibitor and 
the lysine residue at 290 (Table I). After DNA sequenc- 
ing to verify the desired mutation was in place the 
Lur-antitrypsin cDNAs were ligated into a modified 
form of the vector SP64T for transcription of viable 
mRNA in vitro. 
To compare the rates of secretion of different mutant 
cur-antitrypsins equivalent amounts of translationally 
active mRNA were injected into Xenupus oocytes. 
Secretion of the mutant proteins was accessed by in- 
cubating injected oocytes in medium containing L- 
[35S]methionine. Radiolabelled ai-antitrypsin was im- 
munoprecipitated from incubation media and oocyte 
Table I 
Mutant forms of humagcur-antitrypsin a d their ability to form a salt 
bridge with Lys-290 
DNA construct 
Pi M 
Mut Z 
Mut A 
Mut B 
Amino acid 
position 342 
Glu 
LYS 
Ala 
Arg 
Potential for 
salt bridge 
Y 
N 
N 
N 
extracts and analysed by SDS gel electrophoresis 
(Fig. 1). All of the injected transcripts directed the syn- 
thesis of a 54 kDa intracellular protein which re- 
presents partially glycosylated inhibitor. The 
incubation media contained a 58 kDa secreted protein 
formed as a result of further glycosylation of the in- 
tracellular species before export [I 11. To quantitate 
secreted versus intracellular inhibitor radiolabelled 
bands were excised from the gel and incorporation 
measured by liquid scintillation counting. 
M type cYr-antitrypsin and mutant A are equally well 
secreted from oocytes. The absolute level of secretion 
varies among batches of oocytes (e.g. see Table II); 
however, in all experiments the majority of M type and 
Mut A inhibitor synthesised by oocytes was subse- 
quently secreted. The insertion of a basic residue at 
position 342 markedly reduces the level of secretion. 
This applies for both Arg-342 and the naturally occurr- 
ing Z mutation, Lys-342, although the effect of the Glu 
to Arg substitution is less pronounced. 
In addition to the Glu-342 to Lys-342 coding base 
change, a second point mutation is present in the 
Fig. I. Secretion of mutant cur-antitrypsins from Xenopus oocytes. S, secreted protein; 0, protein from oocyte extracts. Control tracks are from 
water-injected oocytes. lmmunoprecipitation and gel electrophoresis were as described in section 2. 
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Tabfe II 
Secretion of mutant crt-antitrypsins from NIH 3T3 ceils and Xerropus 
oocytes 
DNA construct 
Pi M 
Mut 2 
Mut A 
Mut I3 
‘-70 rul-AT secreted 
Oocytes NIH 3T3 ceils 
69 loo 
19 14 
77 89 
28 n.d. 
human Pi 2 allele which codes for a Val to Ala sub- 
stitution at residue 213 [9]. The Z mutant construct 
described here does not carry this second mutation yet 
exhibits the secretory defect found in the natural mu- 
tant. This result suggests that in oocytes, as in other cell 
types [16], the Glu-342 to Lys-342 change is the- sole 
cause of the failure in Z protein export. 
A comparison of the secretory properties of the 
various mutant crl-antitrypsins in oocytes and the 
murine embryonic fibroblast cell line NIH 3T3 is shown 
in Table II. Cultured cells were transfected with the 
modi~ed eukaryotic expression vector pSV2 cont~ning 
cloned mutant al-antitrypsin cDNAs. Antiprotease in 
the medium and cells was assayed by ELISA. Pi M and 
Mut A proteins are secreted more efficiently from 
transfected mammalian cells than from amphibian 
oocytes, However, while absolute amounts of the 
various mutant antiproteases ecreted from the two cell 
types may vary, it is apparent that the qualitative effect 
of the various point mutations on the secretory proper- 
ties of the resultant protein products is constant 
regardless of the cell type used for expression. 
Disruption of the Lys-29O/Glu”342 salt bridge by 
mutagenesis of codon 290 does not radically affect the 
secretion of mutant a,-antitrypsins from Xenopus 
oocytes [ 151 or transfected mammalian cells [16,17]. 
However, substitution of Glu at position 290 will par- 
tially alleviate the affect of the Z mutation and produce 
a level of protein secretion intermediate between Z and 
wild-type 116,231. The results presented here show that 
it is rather the positive nature of Lys-342 in the Z muta- 
tion which causes the secretory defect. Substitution of 
a positively charged arginine residue at this point pro- 
duces a similar, if less extensive, reduction in protein 
export (Fig. 1, mut B), The introduction of a neutral 
alanine residue at position 342 prevents salt bridge for- 
mation but has no negative effect on protein secretion 
(Fig. 1, mut A), the introduction of Gln at position 342 
has a similar effect [16]. Successful export of the 
alanine mutant also suggests that an acidic residue at 
342 is not obligatory for protein transport, 
The proximity of residues 290 and 342 is evident 
from the cryst~lographic structure of crl-antitrypsin 
[ 131. The conservation of Lys-290 and Glu-342 in many 
other members of the serpin protein family further 
underscores the importance of these residues in overall 
protein structure 1141. One possibility is that two highly 
basic side chains in a stericafly restricted space are in- 
compatible with correct folding of the protein or with 
its correct interaction with some cellular element which 
mediates in secretion. However, results presented here 
and by other groups indicate that the interaction bet- 
ween these residues might be more subtle than first 
predicted. 
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